A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SOLANA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 29 Mar 2018 Planned End Date changed from 20 Aug 2018 to 3 Aug 2018.
    • 29 Mar 2018 Planned primary completion date changed from 20 Aug 2018 to 3 Aug 2018.
    • 29 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top